193 related articles for article (PubMed ID: 29197360)
1. Psychometric properties of the expanded prostate cancer index composite - 26 instrument in a cohort of radical prostatectomy patients: theoretical and practical examinations.
Axcrona K; Nilsson R; Brennhovd B; Sørebø Ø; Fosså SD; Dahl AA
BMC Urol; 2017 Dec; 17(1):111. PubMed ID: 29197360
[TBL] [Abstract][Full Text] [Related]
2. Psychometric Assessment of the Chinese Version of the Abbreviated Expanded Prostate Cancer Index Composite (EPIC-26) and the Clinical Practice Version (EPIC-CP) in Chinese Men With Prostate Cancer.
Lam WWT; Tse MA; Ng CNL; Chung EKM; Fielding R
J Pain Symptom Manage; 2017 Jun; 53(6):1085-1090. PubMed ID: 28438583
[TBL] [Abstract][Full Text] [Related]
3. Psychometric testing of the Norwegian version of the Expanded Prostate Cancer Index Composite 26-item version (EPIC-26).
Fosså SD; Storås AH; Steinsvik EA; Myklebust TA; Eri LM; Loge JH; Dahl AA
Scand J Urol; 2016 Aug; 50(4):280-5. PubMed ID: 27049891
[TBL] [Abstract][Full Text] [Related]
4. Patient-reported outcome (PRO) questionnaires for men who have radical surgery for prostate cancer: a conceptual review of existing instruments.
Protopapa E; van der Meulen J; Moore CM; Smith SC
BJU Int; 2017 Oct; 120(4):468-481. PubMed ID: 28437031
[TBL] [Abstract][Full Text] [Related]
5. Validation of the Italian version of the abbreviated expanded prostate Cancer index composite (EPIC-26) in men with prostate Cancer.
Marzorati C; Monzani D; Mazzocco K; Masiero M; Pavan F; Monturano M; Pravettoni G
Health Qual Life Outcomes; 2019 Aug; 17(1):147. PubMed ID: 31464649
[TBL] [Abstract][Full Text] [Related]
6. Portuguese version of the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP): psychometric validation and prospective application for early functional outcomes at a single institution.
Lourenço DB; Amaral BS; Alfer-Junior W; Vasconcellos A; Russo F; Sanchez-Salas R; Bianco B; Wagner AA; Chang P; Moschovas MC; Lemos GC; Carneiro A
BMC Urol; 2020 Oct; 20(1):163. PubMed ID: 33081748
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life in men with localized prostate cancer treated with radiotherapy: validation of an abbreviated version of the Expanded Prostate Cancer Index Composite for Clinical Practice in Spain.
Zapatero A; Maldonado Pijoan X; Gómez-Caamaño A; Pardo Masferrer J; Macías Hernández V; Hervás Morón A; Muñoz García JL; Palacios Eito A; Anguita-Alonso P; González-Junco C; López Torrecilla J
Health Qual Life Outcomes; 2021 Sep; 19(1):223. PubMed ID: 34563208
[TBL] [Abstract][Full Text] [Related]
8. Interpreting Patient Reported Urinary and Sexual Function Outcomes across Multiple Validated Instruments.
Vertosick EA; Vickers AJ; Cowan JE; Broering JM; Carroll PR; Cooperberg MR
J Urol; 2017 Sep; 198(3):671-677. PubMed ID: 28342935
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer.
Wei JT; Dunn RL; Litwin MS; Sandler HM; Sanda MG
Urology; 2000 Dec; 56(6):899-905. PubMed ID: 11113727
[TBL] [Abstract][Full Text] [Related]
10. Psychometric validation of the Spanish version of the Expanded Prostate Cancer Index Composite-26.
Zamora V; Garin O; Suárez JF; Jové J; Castells M; Ferrer F; Gutiérrez C; Guedea F; Boladeras A; Fumadó L; Roselló A; Pastor J; Samper P; Pont À; Ferrer M
World J Urol; 2023 Dec; 41(12):3511-3518. PubMed ID: 37947846
[TBL] [Abstract][Full Text] [Related]
11. Comparison of outcomes between pure laparoscopic vs robot-assisted laparoscopic radical prostatectomy: a study of comparative effectiveness based upon validated quality of life outcomes.
Willis DL; Gonzalgo ML; Brotzman M; Feng Z; Trock B; Su LM
BJU Int; 2012 Mar; 109(6):898-905. PubMed ID: 21933328
[TBL] [Abstract][Full Text] [Related]
12. Psychometric validation of the German version of the EPIC-26 questionnaire for patients with localized and locally advanced prostate cancer.
Sibert NT; Dieng S; Oesterle A; Feick G; Carl G; Steiner T; Minner J; Roghmann F; Kaftan B; Zengerling F; Hinkel A; Beyer B; Heidenreich A; Harke N; Brehmer B; Pfitzenmaier J; Fichtner J; Neisius A; Hammerer P; Wesselmann S; Kowalski C
World J Urol; 2021 Jan; 39(1):11-25. PubMed ID: 31552467
[TBL] [Abstract][Full Text] [Related]
13. Quality of life after radical treatment of prostate cancer: validation of the Italian version of the University of California-Los Angeles Prostate Cancer Index.
Gacci M; Livi L; Paiar F; Detti B; Litwin MS; Bartoletti R; Giubilei G; Cai T; Mariani M; Carini M
Urology; 2005 Aug; 66(2):338-43. PubMed ID: 16098363
[TBL] [Abstract][Full Text] [Related]
14. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure.
Litwin MS; Hays RD; Fink A; Ganz PA; Leake B; Brook RH
Med Care; 1998 Jul; 36(7):1002-12. PubMed ID: 9674618
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the measurement properties of the 26-item Expanded Prostate Cancer Index Composite (EPIC-26) with a multicenter cohort.
Crump RT; Peterson A; Charbonneau C; Carlson KV; Sutherland JM; Baverstock RJ
Can Urol Assoc J; 2020 Apr; 14(4):111-117. PubMed ID: 31702548
[TBL] [Abstract][Full Text] [Related]
16. Validation of the Brazilian version of the Expanded Prostate Cancer Index Composite (EPIC) for patients submitted to radical prostatectomy.
Alves E; Medina R; Andreoni C
Int Braz J Urol; 2013; 39(3):344-52. PubMed ID: 23849583
[TBL] [Abstract][Full Text] [Related]
17. Analysis linking UCLA PCI with Expanded Prostate Cancer Index Composite: an evaluation of health related quality of life in Japanese men with localized prostate cancer.
Namiki S; Takegami M; Kakehi Y; Suzukamo Y; Fukuhara S; Arai Y
J Urol; 2007 Aug; 178(2):473-7; discussion 477. PubMed ID: 17561164
[TBL] [Abstract][Full Text] [Related]
18. The German version of the Expanded Prostate Cancer Index Composite (EPIC): translation, validation and minimal important difference estimation.
Umbehr MH; Bachmann LM; Poyet C; Hammerer P; Steurer J; Puhan MA; Frei A
Health Qual Life Outcomes; 2018 Feb; 16(1):36. PubMed ID: 29458434
[TBL] [Abstract][Full Text] [Related]
19. Creation and Psychometric Validation of the Sexual Minorities and Prostate Cancer Scale (SMACS) in Sexual Minority Patients-The Restore-2 Study.
Polter EJ; Kohli N; Rosser BRS; Talley KMC; Wheldon CW; Hoefer CJ; Wright M; Haggart R; Mitteldorf D; Kilian G; Konety BR; Ross MW; West W
J Sex Med; 2022 Mar; 19(3):529-540. PubMed ID: 35131199
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors.
Szymanski KM; Wei JT; Dunn RL; Sanda MG
Urology; 2010 Nov; 76(5):1245-50. PubMed ID: 20350762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
